Pleased to share an imp study on AI resistance in HR+ breast cancer--led by Suhail in my lab @UnivofDelhi & @CRI_ACTREC! We show insulin sig' mutations, ESR1 upreg', and a novel ESR1-PPP3CA fusion: new therapies to overcome resistance. Thanks @DBTIndia https://t.co/iqL2bdowMV

Pleased to share our twin study (back-2-back), by Vaishakhi Trivedi from K Prabhash gp, @VanitaNoronha , my lab @CRI_ACTREC/@ACTREC_TMC & Dept of Genetics @UnivofDelhi on papillary and anaplastic thyroid ca. https://t.co/h4XUkHBsyj https://t.co/oL5kmiEpD6 https://t.co/mZ1SO4O2Hp

Monika Jaiswal from Sorab Dalal Lab featured in JCS First Person Interview !

We will be happy to host NPDF at Shilpee Lab (SLS, JNU). Visit our lab website ( https://t.co/m6DrBxMfrw) for research interests and recent publications. Please write to me with your CV and research interests

Take a look at our latest article! Superb findings by PhD student Tejashree (@teju1090). Residual #GBM cells divide via #Neosis! Thank you @ANRFIndia and co-authors @Archisman_bnj @MadhuraKetkar @nileshgardi2688 https://t.co/mvVyFV0qlM

Why do some lung cancer patients relapse early on targeted therapy? Our study with Drs. K Prabhash, @VanitaNoronha & team from @TataMemorial in collab with Drs. J Khandare, G Shafi, & team from @onecelldx published in ESMO Open (@ESMO_Open) sheds insights. https://t.co/satjKr2eX8

Research from the lab of @DuttShilpee aims to delineate the #TIS reversal mechanism in glioblastoma #GBM recurrence. The study provide evidence of a novel senolytic drug offering a new seno-therapeutic option for eliminating residual GBM & preventing recurrence. @DrJitendraSingh

Today, on the sad day of the demise of our beloved Ratan Tata, we once again pledge to honour the words ' Tata Memorial' in our name! @TataMemorial @RNTata2000 @tatatrusts

#LungCancer in Southeast Asia, particularly India, is a distinct challenge. Limited access to advanced treatments hinders progress. DBT supports collaborative and innovative efforts to achieve a better understanding through research. @DrJitendraSingh @rajesh_gokhale

Pleased to share the dev' of DOME by @desaisanket12 and team! Thanks @NAR_Cancer_EIC & @ACTREC_TMC. This powerful comput'l framework identifies potential driver mutations, advanc'g personalized cancer therapy with emphas' on VUS ! @CRI_ACTREC @UnivofDelhi https://t.co/KaPpos2LNz

UBE3C-LRP5, novel oncogenic fusion-transcript in oral cancer @ 5.3% in Indian & 1.2% TCGA patients. Kudos to @dbhaskarjnv & Ashwin Butle in collab with Dr. Sudhir Nair! Pyrv' pamoate, an FDA approved dewormer, targets this fusion. A potential game-changer! https://t.co/gqj8MH6T05

Welcome to the Basic Science component of the Third Indian Cancer Congress 2023 event being held at the Jio Convention Centre from Nov 2nd-4th! A day full of a packed schedule. @CRI_ACTREC @ACTREC_TMC

Dear friends,a humble request, if you see this tweet please comment and put your RT on it as our account reach is almost zero. And we are trying to raise fund for our livelihood project of hand embroidery in a village on outskirts of Bhopal

Progesterone improves survival in br ca pts with node +ve. It works by modulating cell' stress response and inflammation.NcRNAs and the SGK1/AP-1/NDRG1 axis are involved. Pg inhibits cell migration and invasion.A precis by Gaurav,@Suhail_Shaad,@MukulGods! https://t.co/HDtcckCzMG

Congratulations, Bhasker! Your work has the potential to make a significant contribution to the field of cancer research and ultimately benefit patients with tongue cancer. Thank you @biopatrika , @CommsBio https://t.co/PRbExABFHo @CRI_ACTREC @ACTREC_TMC @dbhaskarjnv

Contributions from my lab #WorldCancerDay! Thank you @IndianExpress for featuring our oral cancer work led by @dbhaskarjnv,funded by @India_Alliance; & @the_hindu for breast cancer led by @Neelima__Yadav, funded by @DBTIndia VNCI. https://t.co/y5gHDtDmcb, https://t.co/IhqqXEidTf

Pleased to share our work @BCRJournal describing a 3-tiered regulatory network in breast cancer in response to progesterone:how a lincRNA sponges a miRNA to downregulate ER expression! Congratulations to @Neelima__Yadav, @SunderRoma et al. Thank you @ACTREC_TMC and VNCI @DBTIndia

Most Matches Won in a Year by Team 38 - 🇦🇺 in 2003 37 - 🇮🇳 in 2017 35 - 🇦🇺 in 1999 35 - 🇮🇳 in 2018 35 - 🇮🇳 in 2019 35 - 🇮🇳 in 2022* #INDvSA

TMC-SNPdb 2.0, @ACTREC_TMC, is the most exhaustive open-source ref dB of germline variants across 1800 Indians to analyze cancer genomes and other disorders. Thank you, @DBTIndia! Kudos to @desaisanket12, @rkmishra3893, and the team! https://t.co/oFgeTMK8Vy #sciencetechnologynews

Pleased to share a clinically relevant finding by Asim Joshi and Ashwin Butle from the lab with Kumar Prabhash and @VanitaNoronha from TMH. Osimertinib for lung cancer cells harboring low-frequency EGFR T790M mutation. Thank you @serbonline for the funding. https://t.co/bHPTmjqkSH